Addex Therapeutics Ltd
ADXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $2 | $1 | $3 |
| % Growth | -74.9% | 13.4% | -51.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $2 | $1 | $3 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $1 | $8 | $9 |
| G&A Expenses | $2 | $2 | $3 | $8 |
| SG&A Expenses | $2 | $2 | $3 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $1 | $2 |
| Operating Expenses | $3 | $4 | $12 | $18 |
| Operating Income | -$3 | -$2 | -$11 | -$16 |
| % Margin | -681.8% | -139.1% | -741% | -531.7% |
| Other Income/Exp. Net | -$2 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$5 | -$3 | -$11 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $7 | -$11 | -$21 | -$15 |
| % Margin | 1,746% | -654.5% | -1,462.6% | -526.4% |
| EPS | 8.4 | -16.8 | -55.2 | -54 |
| % Growth | 150% | 69.6% | -2.2% | – |
| EPS Diluted | 8.4 | -16.8 | -55.2 | -54 |
| Weighted Avg Shares Out | 1 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$2 | -$10 | -$15 |
| % Margin | -1,149.6% | -135.8% | -734.9% | -512.3% |